5/15
06:30 am
ocup
Ocuphire Pharma, Inc. (NASDAQ: OCUP) was upgraded by analysts at Canaccord Genuity Group Inc. to a "strong-buy" rating.
Medium
Report
Ocuphire Pharma, Inc. (NASDAQ: OCUP) was upgraded by analysts at Canaccord Genuity Group Inc. to a "strong-buy" rating.
5/13
01:27 pm
ocup
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $22.00 to $18.00. They now have a "buy" rating on the stock.
Medium
Report
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $22.00 to $18.00. They now have a "buy" rating on the stock.
5/13
08:09 am
ocup
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
5/10
08:00 am
ocup
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
High
Report
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
5/6
08:00 am
ocup
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
Neutral
Report
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
5/3
08:00 am
ocup
Ocuphire Pharma to Present at the Aegis Virtual Conference
Medium
Report
Ocuphire Pharma to Present at the Aegis Virtual Conference
4/22
08:13 am
ocup
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting [Yahoo! Finance]
4/22
08:00 am
ocup
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
Medium
Report
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
4/11
10:09 am
ocup
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery [Yahoo! Finance]
Medium
Report
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery [Yahoo! Finance]
4/11
10:03 am
ocup
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Medium
Report
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
4/1
07:14 am
ocup
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
High
Report
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
3/20
08:32 am
ocup
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Alliance Global Partners from $24.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Alliance Global Partners from $24.00 to $20.00. They now have a "buy" rating on the stock.
3/13
07:16 am
ocup
Earnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecasts [Yahoo! Finance]
Medium
Report
Earnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecasts [Yahoo! Finance]
3/10
10:11 am
ocup
Ocuphire Pharma Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
Medium
Report
Ocuphire Pharma Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
3/8
08:00 am
ocup
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
High
Report
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
2/23
08:08 am
ocup
Ocuphire Pharma to Present in the BIO CEO & Investor Conference [Yahoo! Finance]
Neutral
Report
Ocuphire Pharma to Present in the BIO CEO & Investor Conference [Yahoo! Finance]
2/23
08:00 am
ocup
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
Low
Report
Ocuphire Pharma to Present in the BIO CEO & Investor Conference